Tomioka-Inagawa, R.; Nakane, K.; Enomoto, T.; Tomioka, M.; Taniguchi, T.; Ishida, T.; Ozawa, K.; Takagi, K.; Ito, H.; Takeuchi, S.;
et al. The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. Biomedicines 2022, 10, 1609.
https://doi.org/10.3390/biomedicines10071609
AMA Style
Tomioka-Inagawa R, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S,
et al. The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. Biomedicines. 2022; 10(7):1609.
https://doi.org/10.3390/biomedicines10071609
Chicago/Turabian Style
Tomioka-Inagawa, Risa, Keita Nakane, Torai Enomoto, Masayuki Tomioka, Tomoki Taniguchi, Takashi Ishida, Kaori Ozawa, Kimiaki Takagi, Hiroki Ito, Shinichi Takeuchi,
and et al. 2022. "The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma" Biomedicines 10, no. 7: 1609.
https://doi.org/10.3390/biomedicines10071609
APA Style
Tomioka-Inagawa, R., Nakane, K., Enomoto, T., Tomioka, M., Taniguchi, T., Ishida, T., Ozawa, K., Takagi, K., Ito, H., Takeuchi, S., Kawase, M., Kawase, K., Kato, D., Takai, M., Iinuma, K., Yokoi, S., Nakano, M., & Koie, T.
(2022). The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. Biomedicines, 10(7), 1609.
https://doi.org/10.3390/biomedicines10071609
